Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly EBITDA Margin came in at 5.58% in Q2 2026, down 1647.0% YoY from 0.36% in Q2 2025, and down 134.06% on a QoQ basis from 16.37% in Q1 2026.
Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of EBITDA Margin data on file, last reported at 5.58% in Q2 2026.
- Quarterly EBITDA Margin fell 1647.0% year-over-year to 5.58% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 9.26% (up 341.0% YoY) and the FY2025 annual result came in at 12.5%, up 1433.0% from the prior year.
- EBITDA Margin retreated to 5.58% in Q2 2026, from 16.37% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 19.69% in Q3 2025 to a low of 25.54% in Q2 2022.
- A 5-year average of 0.24% and a median of 0.24% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 4043 bps — and 2023, when it soared 4116 bps.
- Tracing TEVA's EBITDA Margin over 5 years: stood at 24.2% in 2022, then soared by 170 bps to 16.96% in 2023, then sank by 106 bps to 1.0% in 2024, then soared by 737 bps to 6.37% in 2025, then plunged by 188 bps to 5.58% in 2026.
- The last three EBITDA Margin figures came in at 5.58% (Q2 2026), 16.37% (Q1 2026), and 6.37% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 3.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.58% |
| Mar 31, 2026 | 16.37% |
| Dec 31, 2025 | 6.37% |
| Sep 30, 2025 | 19.69% |
| Jun 30, 2025 | 10.90% |
| Mar 31, 2025 | 13.34% |
| Dec 31, 2024 | -1.00% |
| Sep 30, 2024 | -1.18% |
| Jun 30, 2024 | -0.12% |
| Mar 31, 2024 | -5.71% |
| Dec 31, 2023 | 16.96% |
| Sep 30, 2023 | 8.94% |
| Jun 30, 2023 | -16.86% |
| Mar 31, 2023 | -0.36% |
| Dec 31, 2022 | -24.20% |
| Sep 30, 2022 | 11.79% |
| Jun 30, 2022 | -25.54% |
| Mar 31, 2022 | -19.48% |
| Dec 31, 2021 | 1.90% |
| Sep 30, 2021 | 16.03% |